Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

CKPT's main drug of focus at this time is cosibelimab, an antibody targeting PD-L1 (similar to approved drugs like durvalumab, atezolizumab, and avelumab). They hope that by maintaining a ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

namely AstraZeneca's Imfinzi (durvalumab) and Roche Holding's Tecentriq (atezolizumab) (OTCQX:RHHBY). Given the data below, I believe it has high potential to expand its label and become a first ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab ... of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody ...

If approved, it will compete with immunotherapies based on Roche's Tecentriq (atezolizumab) and AstraZeneca's Imfinzi (durvalumab), which were cleared by the FDA in 2020 and 2022, respectively.

Data from the phase 1 Acclaim-3 trial of quaratusugene ozeplasmid plus atezolizumab in extensive-stage small cell lung cancer showed no dose-limiting toxicities, with the recommended dose set at 0.12 ...

ICIs include inhibitors targeting Programmed Cell Death 1 (PD-1) (sintilimab, tislelizumab, camrelizumab, pembrolizumab) and Programmed Cell Death Ligand 1 (PD-L1) inhibitors (atezolizumab, durvalumab ...

Recently, the combination of anti-PD-L1 antibody atezolizumab and the VEGF inhibitor bevacizumab ... III trial examining the adjuvant combination PD-L1 monoclonal antibody durvalumab and bevacizumab ...

Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum ... discusses the anticipated clinical benefits of adding tarlatamab to ...